Using a blood test to guide breast cancer therapy
Part of Cancer, Skin clinical trials.
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with early-stage breast cancer that has not spread to distant organs.
- Your tumor is hormone receptor-positive (ER and/or PR positive) and HER2-negative.
- You have had surgery to remove the tumor completely.
- You have not taken CDK4/6 inhibitor medications before.
- You are willing to provide a tumor tissue sample for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This study looks at whether a simple blood test (ctDNA) can tell if your current hormone therapy is starting to stop working, and whether switching to a different hormone therapy early would be better. It aims to keep your cancer under control longer with fewer side effects.
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.